FDA Cancels Advisory Committee Meeting On J&J’s Paliperidone ER
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is currently conducting head-to-head trials against AstraZeneca’s antipsychotic Seroquel.
You may also be interested in...
J&J Expects Paliperidone To Receive FDA “Approvable” Letter
However, the company plans to move very quickly toward approval.
J&J Expects Paliperidone To Receive FDA “Approvable” Letter
However, the company plans to move very quickly toward approval.
Wyeth’s Desvenlafaxine Advisory Committee Is Cancelled
FDA determines that its questions have been satisfactorily answered.